CA2004202A1 - Traitement intralesionnel de l'epithelioma epidermoide a l'aide d'alpha-interferon humain recombinant - Google Patents

Traitement intralesionnel de l'epithelioma epidermoide a l'aide d'alpha-interferon humain recombinant

Info

Publication number
CA2004202A1
CA2004202A1 CA2004202A CA2004202A CA2004202A1 CA 2004202 A1 CA2004202 A1 CA 2004202A1 CA 2004202 A CA2004202 A CA 2004202A CA 2004202 A CA2004202 A CA 2004202A CA 2004202 A1 CA2004202 A1 CA 2004202A1
Authority
CA
Canada
Prior art keywords
cell carcinoma
squamous cell
recombinant human
intralesionally
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2004202A
Other languages
English (en)
Other versions
CA2004202C (fr
Inventor
Daniel J. Tanner
Edwin A. Peets
Kenneth A. Smiles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CA2004202A1 publication Critical patent/CA2004202A1/fr
Application granted granted Critical
Publication of CA2004202C publication Critical patent/CA2004202C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002004202A 1988-12-01 1989-11-29 Traitement intralesionnel de l'epithelioma epidermoide a l'aide d'alpha-interferon humain recombinant Expired - Fee Related CA2004202C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27831588A 1988-12-01 1988-12-01
US278,315 1988-12-01

Publications (2)

Publication Number Publication Date
CA2004202A1 true CA2004202A1 (fr) 1990-06-01
CA2004202C CA2004202C (fr) 2001-02-13

Family

ID=23064525

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002004202A Expired - Fee Related CA2004202C (fr) 1988-12-01 1989-11-29 Traitement intralesionnel de l'epithelioma epidermoide a l'aide d'alpha-interferon humain recombinant

Country Status (14)

Country Link
EP (2) EP0372809B1 (fr)
JP (1) JPH0647556B2 (fr)
KR (1) KR950011889B1 (fr)
AT (1) ATE92333T1 (fr)
AU (1) AU634511B2 (fr)
CA (1) CA2004202C (fr)
DE (1) DE68908119T2 (fr)
DK (1) DK103891A (fr)
ES (1) ES2058555T3 (fr)
IE (1) IE63121B1 (fr)
IL (1) IL92495A (fr)
MY (1) MY107071A (fr)
WO (1) WO1990006135A1 (fr)
ZA (1) ZA899113B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9139091A (en) * 1990-12-14 1992-07-08 Schering Corporation Oral administration of alpha interferon to treat lung malignancies
PT99837A (pt) * 1990-12-21 1992-12-31 Schering Corp Processo para a preparacao de composicoes farmaceuticas contendo interferao alfa e metodo para administracao de interferao alfa por inalacao oral para tratar asma e doencas pulmonares proliferativas nao malignas
US7294332B2 (en) 1995-10-04 2007-11-13 Schering Corporation Combination therapy (temozolomide and α-IFN) for advanced cancer
DE69625373T2 (de) * 1995-10-04 2003-05-15 Schering Corp., Kenilworth Kombination von temozolomide und alpha-interferon zur behandlung von fortgeschrittenem krebs

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0077063B1 (fr) * 1981-10-13 1988-03-16 Exovir, Inc. Compositions contenant de l'interféron et application de ces compositions dans le traitement des infections herpétiques, lésions prémalignes de la peau, malignités de la peau et psoriasis
ZA873743B (en) * 1986-05-27 1987-11-25 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon

Also Published As

Publication number Publication date
ES2058555T3 (es) 1994-11-01
JPH0647556B2 (ja) 1994-06-22
DE68908119T2 (de) 1993-11-18
ZA899113B (en) 1990-08-29
KR950011889B1 (ko) 1995-10-12
MY107071A (en) 1995-09-30
JPH04500678A (ja) 1992-02-06
KR900701311A (ko) 1990-12-01
IL92495A (en) 1995-05-26
IE893828L (en) 1990-06-01
DK103891D0 (da) 1991-05-31
AU634511B2 (en) 1993-02-25
EP0372809A1 (fr) 1990-06-13
EP0372809B1 (fr) 1993-08-04
DK103891A (da) 1991-05-31
EP0446279A1 (fr) 1991-09-18
IE63121B1 (en) 1995-03-22
WO1990006135A1 (fr) 1990-06-14
DE68908119D1 (de) 1993-09-09
AU4802590A (en) 1990-06-26
ATE92333T1 (de) 1993-08-15
CA2004202C (fr) 2001-02-13
IL92495A0 (en) 1990-08-31

Similar Documents

Publication Publication Date Title
EP0253094A3 (en) Use of prostaglandin d2-active substances in the treatment of ocular hypertension and glaucoma
NO176665C (no) Fremgangsmåte for fremstilling av ikke-glykosylert IL-6 og vektor for utskillelse derav
AU4658489A (en) Use of acetyl d-carnitine in the therapeutic treatment of glaucoma
AU3072989A (en) Skin treatment composition
ATE131493T1 (de) Polypeptide und polypeptidanaloge mit inhibitorischer aktivität gegenüber menschlicher elastase
AU581574B2 (en) Fabric treatment to improve dyeability thereof
AU2308992A (en) Cysteine depleted il-6 muteins
DE68917353D1 (de) N-Alkoxyalkylamide von Hydroxysauren und sie enthaltende Hautbehandlungszubereitungen.
AU4524689A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
MY107071A (en) Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
EP0267684A3 (en) Human leukocyte interferon composition and skin treatment
EP0294538A3 (en) Use of nigericin in the treatment of viral diseases
EP0276120A3 (en) Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
AU5042890A (en) Composition and treatment with peptide combinations
AU3857389A (en) Treatment of genital warts with a combination of podophyllin and recombinant dna human alpha interferon
EP0278715A3 (fr) Utilisation d'interféron gamma humain pour le traitement du carcinome de cellules basales
AU5234586A (en) Improvements relating to the treatment control and preventionof rhinovirus infections
AU3327789A (en) Expression of the hiv 24 kda 24 gag protein in methylotrophic yeast
AU7696087A (en) Recombinant human tissue plasminogen activator composition
Koren The antiviral activity of interferon at the cellular and molecular level.
AU8260287A (en) N-phenyl-N-carboxythioureas and their use in the control of pests
HU900202D0 (en) Process for manufacturing of pharmaceutical compositions comprising gamma-interferon suitable to treatment of ovarion cancer
IE881242L (en) Human lymphokine activated killer cells
IE882290L (en) Treatment of infections with tumor necrosis factor

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed